Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells
Open Access
- 10 October 2017
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 9 (4), 42
- https://doi.org/10.3390/pharmaceutics9040042
Abstract
Many drugs can cause unexpected muscle disorders, often necessitating the cessation of an effective medication. Inhibition of monocarboxylate transporters (MCTs) may potentially lead to perturbation of l-lactic acid homeostasis and muscular toxicity. Previous studies have shown that statins and loratadine have the potential to inhibit l-lactic acid efflux by MCTs (MCT1 and 4). The main objective of this study was to confirm the inhibitory potentials of atorvastatin, simvastatin (acid and lactone forms), rosuvastatin, and loratadine on l-lactic acid transport using primary human skeletal muscle cells (SkMC). Loratadine (IC50 31 and 15 µM) and atorvastatin (IC50 ~130 and 210 µM) demonstrated the greatest potency for inhibition of l-lactic acid efflux at pH 7.0 and 7.4, respectively (~2.5-fold l-lactic acid intracellular accumulation). Simvastatin acid exhibited weak inhibitory potency on l-lactic acid efflux with an intracellular lactic acid increase of 25–35%. No l-lactic acid efflux inhibition was observed for simvastatin lactone or rosuvastatin. Pretreatment studies showed no change in inhibitory potential and did not affect lactic acid transport for all tested drugs. In conclusion, we have demonstrated that loratadine and atorvastatin can inhibit the efflux transport of l-lactic acid in SkMC. Inhibition of l-lactic acid efflux may cause an accumulation of intracellular l-lactic acid leading to the reported drug-induced myotoxicity.This publication has 24 references indexed in Scilit:
- Data-driven prediction of adverse drug reactions induced by drug-drug interactionsBMC Pharmacology and Toxicology, 2017
- Statin myopathy: navigating the mazeCurrent Medical Research and Opinion, 2016
- Deaths: Final Data for 2014.2016
- Adverse drug reactions in the elderlyJournal of Pharmacology and Pharmacotherapeutics, 2013
- Statin induced myotoxicityEuropean Journal of Internal Medicine, 2012
- Drug-related Myopathies of Which the Clinician Should Be AwareCurrent Rheumatology Reports, 2010
- Drug-induced myopathies.2009
- Statin-induced apoptosis and skeletal myopathyAmerican Journal of Physiology-Cell Physiology, 2006
- Fenofibrate-induced myopathy.2004
- The genetic basis of variability in drug responsesNature Reviews Drug Discovery, 2002